Previous 10 | Next 10 |
Charles River Laboratories International Inc. (CRL) is expected to report $2.35 for Q3 2023
2023-11-07 11:50:34 ET More on Charles River Laboratories Charles River Laboratories: Diving Into The Lab (Rating Upgrade) Charles River Laboratories International, Inc. (CRL) Q2 2023 Earnings Call Transcript Charles River falls on Investor Day amid growth concerns ...
2023-11-05 23:46:57 ET In the upcoming week of November, investors can anticipate a flurry of quarterly reports from major companies, promising significant market activity. Notable among them is Disney ( NYSE: DIS ), a household name set to disclose its financial performance. ...
2023-11-01 13:08:40 ET Shares of IQVIA Holdings ( NYSE: IQV ) reached the lowest level in over a year on Wednesday after the contract research firm lowered its full-year outlook with its Q3 2023 financials, dragging its rivals in the industry. Notable decliners include Inotiv ( ...
2023-10-30 12:28:25 ET More on Revvity Revvity: Recent Investments, Acquisitions, Not Pulling Economic Weight (Rating Downgrade) Revvity, Inc. (RVTY) Q2 2023 Earnings Call Transcript Revvity, Inc. 2023 Q2 - Results - Earnings Call Presentation Revvity misses ...
2023-10-24 19:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a new e-commerce ordering experience, offering clients real-time access into research model availability and pricing, as well as immediate order confirmation. The introduction of real-time ordering for Charles River’...
Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2023 financial results on Wednesday, November 8 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 8 th , at 8:30 a.m. ET. Investors...
Recently established regulatory guidelines make testing for pediatric indications a necessary step in oncology research and development Charles River Laboratories International, Inc. (NYSE: CRL) today announced the ability to conduct preclinical cancer research using ITCC-P4’s ...
Company selected as Energy Star Top Project of the Year for Energy Recovery System, and develops industry partnerships to align with sustainable initiatives Charles River Laboratories International, Inc. (NYSE: CRL) today announced that, while working toward previously announced environ...
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
Charles River Laboratories International Inc. Website:
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7 th , at 9:00 a.m. ET. Investors wi...
Critical starting material manufacture for therapeutic targeting high unmet need ophthalmology indication Charles River Laboratories International, Inc. (NYSE: CRL) and AAVantgarde today announced a contract development and manufacturing organization (CDMO) agreement to produce Good...
Lentiviral vector CDMO collaboration to support advanced cell therapies for hematological cancers Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract...